Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Metastatic Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis; Drug · Biological · Genetic + 1 more
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type I Diabetes
Interventions: Ladarixin, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: TD-4208; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Nicotine Vaping, Nicotine, Vaping
Interventions: CA35, CM35, Cig; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 24 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Healthy Adults
Interventions: KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg, KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: Enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: MEDI0382 Formulation 2, MEDI0382 Formulation 3; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: MK-1167; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy Participants
Interventions: Mitapivat, Midazolam; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: NASH
Interventions: Midazolam, Caffeine, Rosuvastatin, EDP-305; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Nalmefene; Drug
Lead sponsor: Tharimmune Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Major Depressive Disorder
Interventions: CERC-301, Placebo; Drug · Other
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 21 more

Conditions: Obesity
Interventions: Keys to Healthy Family Child Care Homes; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Months and older
Enrollment: 805 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Wilson Disease
Interventions: ALXN1840, Bupropion Hydrochloride; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions: NKTR-118, Ketoconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cardiotoxicity
Interventions: Inhaled placebo, Oral placebo, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Cannabis Use Disorder
Interventions: Emotional Engagement Distress Tolerance Intervention, Health Education Intervention; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Advanced Solid Tumors
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Concussion
Interventions: Mindfulness and Yoga Training; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 15 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Tuberculosis
Interventions: PA-824 1000 mg; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteer
Interventions: Palbociclib, Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Nadi Shuddhi, Shoonya Meditation; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 25 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: BMS-986165, MMF; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Solid Malignancies
Interventions: CT7001, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more

Search by objective public record fields.

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

Phase 1A Study of the Safety of KSP/QRH Dimer

A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)

A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

An Evaluation of The Absolute Bioavailability of TH104

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Keys to Healthy Family Child Care Homes

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

Staccato Prochlorperazine Thorough QT/QTc

Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users

Study of MLN8237 in Participants With Advanced Solid Tumors

Mindfulness and Yoga Training for Athletes With Concussion (MYTAC)

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies